ADLM 2025 – Chicago: Highlights and Event Recap

ADLM 2025 was held in Chicago, IL, USA, from July 27-31. The Association for Diagnostics & Laboratory Medicine event hosted global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine. Popular topics included:

• Artificial intelligence and LLMs for quality, decision support, and operations

• LC‑MS/MS implementation, harmonization, and inter‑laboratory transfer

• Point‑of‑care testing (POCT) adoption and stewardship

• Evolving oversight of laboratory‑developed tests (LDTs) and compliance

• Cardiometabolic risk: CGM quality, eGFR reporting, cystatin C, and troponin cutoffs

• Neurodegeneration and brain injury biomarkers (Alzheimer’s blood tests; GFAP/UCH‑L1 for TBI)

• Pediatric testing access, reference intervals, and low‑volume specimens

• Microbiome diagnostics and precision infectious disease testing

• Equity, access, and outreach models for community and rural care

• Practical lab leadership: crisis management, marketing, and workforce development

→ Biointron’s Highlighted Points:

1. AI & LLMs Move From Hype to Hands‑On

• Sessions stress‑tested generative AI for method validation support, QC triage, and clinical decision support.

• Real‑world case studies (e.g., “Bad, better, best: Putting generative AI to the test” and the LLM foundations session) emphasized guardrails, explainability, and integration with LIS/CPOE.

• AI‑assisted literature mining and sequence/epitope analytics can accelerate antibody panel design while documenting explainable rationale for regulated environments.

2. Mass Spec Harmonization Enables Reliable Protein & Small‑Molecule Panels

• Updated guidance on LC‑MS/MS implementation and “multiple instruments, identical results” harmonization reinforce the path to cross‑site comparability.

• When developing antibody reagents for LC‑MS immuno‑affinity workflows, or orthogonal confirmation of immunoassays, early alignment to shared QA metrics (matrix effects, commutability, carryover) reduces rework downstream.

3. Neuro Biomarkers Break Through

• Programs on TBI (GFAP & UCH‑L1) and Alzheimer’s disease blood biomarkers (updated criteria and staging) underscored rapid clinical translation.

• High‑specificity binders and interference‑resistant assay formats (e.g., fragment antibodies to reduce heterophilic interference) are key for low‑abundance CNS markers.

4. Cardiometabolic Diagnostics Get Sharper

• Debates around cystatin C integration, sex‑specific troponin cutoffs, CGM quality, and diabetes screening (1‑hour glucose) highlight a shift toward more precise risk stratification.

• Calibrator design, commutable controls, and cross‑reactivity testing should be prioritized in antibody kit development targeting cardiometabolic panels.

5. LDT Oversight, Reference Intervals & Preanalytical Realities

• From federal oversight of LDTs to practical reference interval determination and analytical/preanalytical error mitigation, compliance themes were front‑and‑center.

• Documented validation roadmaps (accuracy, linearity, LoD/LoQ) and matrix‑aware antibody screening speed regulatory review and customer tech transfer.

6. Access, POCT, and Remote Sampling Expand the Lab’s Reach

• POCT adoption strategies, microsampling (VAMS), and equity‑focused sessions showcased models that bring testing closer to patients while maintaining quality.

• Assay formats compatible with finger‑stick volumes and robust to ambient shipping conditions will see growing demand in decentralized workflows.

Thank you to everyone who visited our booth at ADLM to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.